RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

Latest press releases

RetinAI Expands Operations to Set Up a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

RetinAI, a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, located in Boston, MA. This expansion will support further growth within the U.S. market, building upon existing collaborations with U.S.-based pharmaceutical companies and its partnership with Heidelberg Engineering to distribute RetinAI’s Disease AI Apps for research use in the U.S. The Boston office will be RetinAI’s second location, in addition to its Bern headquarters.

RetinAI will attend EURETINA 2022 from September 1st to 4th in Hamburg

RetinAI will attend the 22nd EURETINA Congress, from September 1st to 4th, at the CCH (Congress Centre Hamburg) in Hamburg, Germany. EURETINA 2022 attendees will get first-hand insights on the company’s two new products: Our new data management platform, Discovery CORE, designed to share data in a privacy-preserving and secure manner across a network of collaborators, fostering and facilitating knowledge network building, vendor-neutral collaborative data analysis & management, education, training and teleophthalmology. Our Disease Evaluation Apps on Heidelberg Engineering’s secure data workflow solution, called AppWay, for connecting to AI applications.

RetinAI attends OIS Retina Innovation Summit and ASRS 2022 Annual Meeting from July 13th to 16th in New York

RetinAI will attend the OIS Retina Innovation Summit on July 13th at the Edison Ballroom NYC, and the ASRS 2022 Annual Meeting, from July 14th to 16th, at the Javits Convention Center in New York. ASRS attendees who visit RetinAI at Booth #625 will benefit from learning and seeing live demos on RetinAIs latest products and services.

RetinAI announces multi-year software license and services agreement for RetinAI Discovery® UNITY platform

RetinAI announces a multi-year license and services agreement with Novartis AG (“Novartis”) for its Discovery® UNITY platform. Discovery UNITY is RetinAI’s top of the line enterprise-wide solution to aggregate imaging data for global organizations, including data from clinical and real-world evidence studies, with AI that can be applied to improve understanding of patient populations and outcomes at scale.

Latest updates

Machine learning can predict anti-VEGF treatment demand in a Treat-and-Extend regimen for patients with nAMD, DME and RVO associated ME

2 new Posters in ARVO 2021 Virtual

We are very excited of our team and collaborators presenting 2 posters in ARVO 2021! One Poster on 'Longitudinal analysis of Retinal Pigment Epithelium Atrophy progression using an automated segmentation algorithm' providing segmentation analysis over 5 years using deep learning,
and a poster on 'Automated fovea and optic disc detection in the presence of occlusions in Fundus SLO Images'.

New publication on TVST - Automated quantification of pathological fluids in neovascular age-related degeneration, and it's repeatability using deep learning

In this peer reviewed publication, we develop a reliable algorithm for the automated identification, localization, and volume measurement of exudative manifestations in neovascular age-related macular degeneration (nAMD), including intraretinal (IRF), subretinal fluid (SRF), and pigment epithelium detachment (PED), using a deep-learning approach. The deep-learning algorithm can simultaneously acquire a high level of performance for the identification and volume measurements of IRF, SRF, and PED in nAMD, providing accurate and repeatable predictions. Including layer segmentation during training and squeeze-excite block in the network architecture were shown to boost the performance. Source: Mantel et al. , TVST 2021, 10 (17) - Authors: Irmela Mantel; Agata Mosinska; Ciara Bergin; Maria Sole Polito; Jacopo Guidotti; Stefanos Apostolopoulos; Carlos Ciller; Sandro De Zanet

Translation Vision Science and Technology

RetinAI receives ISO 13485:2016 certification

Retinai has just received the ISO 13485 certification, a recognition awarded by regulatory bodies and necessary for companies willing to develop & commercialise Medical Devices. RetinAI Discovery, our platform for medical image and data management in ophthalmology, is now getting ready to be commercialised to clinics as a medical device. We are extremely proud of the team for achieving the certification!

Contact us for more informations! We are happy to hear from you!